PL2729499T3 - Wielospecyficzne zmutowane fragmenty fab przeciwciał - Google Patents
Wielospecyficzne zmutowane fragmenty fab przeciwciałInfo
- Publication number
- PL2729499T3 PL2729499T3 PL12748555T PL12748555T PL2729499T3 PL 2729499 T3 PL2729499 T3 PL 2729499T3 PL 12748555 T PL12748555 T PL 12748555T PL 12748555 T PL12748555 T PL 12748555T PL 2729499 T3 PL2729499 T3 PL 2729499T3
- Authority
- PL
- Poland
- Prior art keywords
- multispecific
- fab fragments
- antibody fab
- mutated antibody
- mutated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305872A EP2543680A1 (en) | 2011-07-07 | 2011-07-07 | Multispecific mutated antibody Fab fragments |
| EP12748555.5A EP2729499B1 (en) | 2011-07-07 | 2012-07-06 | Multispecific mutated antibody fab fragments |
| PCT/IB2012/053482 WO2013005194A2 (en) | 2011-07-07 | 2012-07-06 | Multispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2729499T3 true PL2729499T3 (pl) | 2021-03-08 |
Family
ID=44904654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20168633.4T PL3872095T3 (pl) | 2011-07-07 | 2012-07-06 | Wieloswoiste zmutowane fragmenty fab przeciwciał |
| PL12748555T PL2729499T3 (pl) | 2011-07-07 | 2012-07-06 | Wielospecyficzne zmutowane fragmenty fab przeciwciał |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20168633.4T PL3872095T3 (pl) | 2011-07-07 | 2012-07-06 | Wieloswoiste zmutowane fragmenty fab przeciwciał |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9631031B2 (pl) |
| EP (4) | EP2543680A1 (pl) |
| JP (1) | JP6305332B2 (pl) |
| KR (1) | KR102095886B1 (pl) |
| CN (1) | CN103797033B (pl) |
| CA (2) | CA3099509C (pl) |
| CY (1) | CY1123484T1 (pl) |
| DK (2) | DK2729499T3 (pl) |
| ES (2) | ES2969070T3 (pl) |
| FI (1) | FI3872095T3 (pl) |
| HR (2) | HRP20240005T1 (pl) |
| HU (2) | HUE051620T2 (pl) |
| LT (2) | LT2729499T (pl) |
| MX (1) | MX351418B (pl) |
| PL (2) | PL3872095T3 (pl) |
| PT (2) | PT3872095T (pl) |
| SI (2) | SI3872095T1 (pl) |
| WO (1) | WO2013005194A2 (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2802344C (en) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| CA3202536A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla, Llc | Multi-specific monoclonal antibodies |
| BR112015012385A2 (pt) | 2012-11-28 | 2019-08-27 | Zymeworks Inc | constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| WO2014124326A1 (en) | 2013-02-08 | 2014-08-14 | Stem Centrx, Inc. | Novel multispecific constructs |
| WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| WO2015181805A1 (en) | 2014-05-28 | 2015-12-03 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| GB201411420D0 (en) * | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| CN104371974B (zh) * | 2014-10-24 | 2017-03-22 | 杭州阿诺生物医药科技股份有限公司 | 一种自体外周血淋巴细胞cik的培养方法 |
| WO2016068803A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
| AU2016252773B2 (en) * | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
| JP6622392B2 (ja) * | 2015-10-02 | 2019-12-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体 |
| JP6932693B2 (ja) * | 2015-10-08 | 2021-09-08 | ザイムワークス，インコーポレイテッド | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 |
| EP3397646A1 (en) * | 2015-12-28 | 2018-11-07 | Massachusetts Institute of Technology | Bispecific antibodies having constant region mutations and uses therefor |
| SG11201808289SA (en) | 2016-03-25 | 2018-10-30 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| ES2952951T3 (es) * | 2016-04-28 | 2023-11-07 | Biomunex Pharmaceuticals | Anticuerpos biespecíficos dirigidos a EGFR y HER2 |
| KR102682118B1 (ko) * | 2016-04-29 | 2024-07-08 | 주식회사유한양행 | Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도 |
| SG11201900373WA (en) * | 2016-07-19 | 2019-02-27 | Ibentrus Inc | Bispecific proteins and methods for preparing same |
| WO2018071913A2 (en) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| SG11201906313SA (en) * | 2017-01-09 | 2019-08-27 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| JP7432365B2 (ja) * | 2017-03-27 | 2024-02-16 | ビオミューネクス・ファルマシューティカル | 安定な多重特異性抗体 |
| RS63663B1 (sr) | 2017-04-03 | 2022-11-30 | Hoffmann La Roche | Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15 |
| CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| FR3072686B1 (fr) | 2017-10-25 | 2021-10-22 | Centre Nat Rech Scient | Systeme d'expression baculovirus |
| CN110573531B (zh) * | 2018-01-15 | 2021-04-02 | 天境生物科技(上海)有限公司 | 经修饰的Cκ和CH1结构域 |
| AU2019412561A1 (en) * | 2018-12-24 | 2021-08-12 | Sanofi | Multispecific binding proteins with mutant Fab domains |
| EP3674316A1 (en) | 2018-12-24 | 2020-07-01 | Sanofi | Multispecific binding proteins with mutant fab domains |
| WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
| EP4322938A1 (en) | 2021-04-14 | 2024-02-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New method to improve nk cells cytotoxicity |
| WO2022219076A1 (en) | 2021-04-14 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
| CN114106192B (zh) * | 2021-12-20 | 2024-06-14 | 广州爱思迈生物医药科技有限公司 | 双特异性抗体及其应用 |
| AU2023228330A1 (en) | 2022-03-02 | 2024-09-19 | Biomunex Pharmaceuticals | Bispecific antibodies binding to her-3 and to either her-2 or egfr |
| WO2024192389A2 (en) | 2023-03-16 | 2024-09-19 | Genzyme Corporation | Treatment of dry age-related macular degeneration |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| DE122009000068I2 (de) * | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2176574T3 (es) * | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DK2857516T3 (en) * | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| US20090182127A1 (en) * | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| EP2069401A4 (en) * | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
| WO2009015518A1 (fr) | 2007-08-02 | 2009-02-05 | Essence Technology Solution, Inc. | Procédé de communication pour fournir un téléphone multimode voix sur ip dans un dispositif mobile |
| HUE028536T2 (en) * | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
| CN102625813A (zh) * | 2008-06-20 | 2012-08-01 | 诺华公司 | 具有降低的聚集的免疫球蛋白 |
| MX2010014062A (es) * | 2008-06-20 | 2011-02-22 | Novartis Ag | Metodos para identificar regiones de enlace a macromoleculas y con tendencia a la agregacion en proteinas y usos de las mismas. |
| EP2342231A1 (en) * | 2008-09-26 | 2011-07-13 | Roche Glycart AG | Bispecific anti-egfr/anti-igf-1r antibodies |
| US9067986B2 (en) * | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US8679500B2 (en) | 2009-05-14 | 2014-03-25 | Institute National De La Sante Et De La Recherche Medicale (Inserm) | Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related diseases |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
-
2011
- 2011-07-07 EP EP11305872A patent/EP2543680A1/en not_active Ceased
-
2012
- 2012-07-06 CA CA3099509A patent/CA3099509C/en active Active
- 2012-07-06 KR KR1020147003184A patent/KR102095886B1/ko active IP Right Grant
- 2012-07-06 EP EP20168633.4A patent/EP3872095B1/en active Active
- 2012-07-06 LT LTEP12748555.5T patent/LT2729499T/lt unknown
- 2012-07-06 CN CN201280033847.9A patent/CN103797033B/zh active Active
- 2012-07-06 LT LTEP20168633.4T patent/LT3872095T/lt unknown
- 2012-07-06 EP EP23173235.5A patent/EP4252772A3/en active Pending
- 2012-07-06 HU HUE12748555A patent/HUE051620T2/hu unknown
- 2012-07-06 PT PT201686334T patent/PT3872095T/pt unknown
- 2012-07-06 FI FIEP20168633.4T patent/FI3872095T3/fi active
- 2012-07-06 WO PCT/IB2012/053482 patent/WO2013005194A2/en active Application Filing
- 2012-07-06 PL PL20168633.4T patent/PL3872095T3/pl unknown
- 2012-07-06 HR HRP20240005TT patent/HRP20240005T1/hr unknown
- 2012-07-06 DK DK12748555.5T patent/DK2729499T3/da active
- 2012-07-06 US US14/130,773 patent/US9631031B2/en active Active
- 2012-07-06 HU HUE20168633A patent/HUE066721T2/hu unknown
- 2012-07-06 PL PL12748555T patent/PL2729499T3/pl unknown
- 2012-07-06 SI SI201232054T patent/SI3872095T1/sl unknown
- 2012-07-06 JP JP2014518059A patent/JP6305332B2/ja active Active
- 2012-07-06 CA CA2841039A patent/CA2841039C/en active Active
- 2012-07-06 PT PT127485555T patent/PT2729499T/pt unknown
- 2012-07-06 ES ES20168633T patent/ES2969070T3/es active Active
- 2012-07-06 MX MX2014000234A patent/MX351418B/es active IP Right Grant
- 2012-07-06 SI SI201231812T patent/SI2729499T1/sl unknown
- 2012-07-06 EP EP12748555.5A patent/EP2729499B1/en active Active
- 2012-07-06 DK DK20168633.4T patent/DK3872095T3/da active
- 2012-07-06 ES ES12748555T patent/ES2816701T3/es active Active
-
2017
- 2017-03-20 US US15/463,498 patent/US10815310B2/en active Active
-
2020
- 2020-07-28 HR HRP20201191TT patent/HRP20201191T1/hr unknown
- 2020-07-29 CY CY20201100697T patent/CY1123484T1/el unknown
- 2020-08-18 US US16/996,534 patent/US20210040235A1/en active Pending
- 2020-08-18 US US16/996,510 patent/US11945879B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2729499T3 (pl) | Wielospecyficzne zmutowane fragmenty fab przeciwciał | |
| HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
| EP2722343A4 (en) | ANTI-ERBB3 ANTIBODIES | |
| LT2794658T (lt) | Bispecifinė antikūno molekulė | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| EP2922874A4 (en) | BISPECIFIC ANTIBODIES | |
| EP2758080A4 (en) | ANTICANCER IMMUNOTHERAPY | |
| IL229618B (en) | An isolated antibody that binds fcrn | |
| EP2686349A4 (en) | METHODS OF ANTIBODY SCREENING | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201116342D0 (en) | Antigen combinations | |
| HK1175486A1 (zh) | 抗腫瘤壞死因子α的人源化抗體 |